105816-04-4
105816-04-4 structure
- Name: Nateglinide
- Chemical Name: nateglinide
- CAS Number: 105816-04-4
- Molecular Formula: C19H27NO3
- Molecular Weight: 317.423
- Catalog: API Hormone and endocrine-regulating drugs Pancreatic hormones and other blood sugar regulating drugs
- Create Date: 2018-04-06 08:00:00
- Modify Date: 2026-06-29 19:16:43
-
Nateglinide is an insulin secretagog agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).Target: OthersNateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those na?ve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound [1-3].
| Name | nateglinide |
|---|---|
| Synonyms |
Starsis
NATAGLINIDE SDZ DJN 608 N-(TRANE-4-ISO-PROPYLCYLOLOHEXYLCBOXYL)-D-PHENYLPROPYLICACID(NATEGLINIDE) Stsis-d5 Nagteglinide Nateglinide 105-4 CAS NO.105-4 N-(4α-Isopropylcyclohexane-1β-yl)carbonyl-D-phenylalanine H-TYPE NATEGLINIDE MFCD00875706 SDZ-DJN 608-d5 Fastic D-Nateglinide-d5 Senaglinide Stlix-d5 N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine-d5 (-)-n-(trans-4-isopropylcyclohexanecbonyl)-d-phenylalanine (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Senaglinide-d5 N-(Trans-4-Isopropylcyclohexyl-1-carbonyl)-D-Phenylalamine (2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid AY 4166-d5 Nagelienai nateglinide NATEGLINIDE N-{[trans-4-(Propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanin Nateglinide(A-4166) Fastic-d5 N-(trans-4-isopropylcyclohexylcbonyl)-D-phenylamine Stlix DS-d5 N-[[4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]- (9CI) n-(trans-4-Isopropylcylolohexylcboxyl)-d-phenylpropylicacid STLIX N-[[4α-(1-Methylethyl)cyclohexan-1β-yl]carbonyl]-D-phenylalanine (R)-2-((1r,4R)-4-isopropylcyclohexanecboxamido)-3-phenylpropanoic acid Nateglinide an insulin secretagog agent Glinate DJN 608-d5 Nateglinide intermediate Starlix Glinate-d5 (2R)-2-{[(trans-4-Isopropylcyclohexyl)carbonyl]amino}-3-phenylpropanoic acid trans-d-phenylalanin Stlix, A-4166, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine (-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine Natelide N-[[TRANS-4-(1-METHYLETHYL)CYCLOHEXYL]carbonyl]-D-PHENYLALANINE N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine Starlix DS D-Nateglinide N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine SDZ-DJN Fastic, N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine, Stlix, Stsis Nateglinide(3-Phenyl-2-(4-propan-2-ylcyclohexyl)cbonylamino-propanoicacid) Natelide-d5 N-[[4β-(1-Methylethyl)cyclohexan-1α-yl]carbonyl]-D-phenylalanine Nateglinide Solution, 100ppm Nateglinide (Stlix) D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, trans trans-n-((4-(1-methylethyl)cyclohexyl)carbonyl)-d-phenylalanine Stlix DS N-{[trans-4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine Nateglinide(H) DJN 608 3-phenyl-2-(4-propan-2-ylcyclohexyl)cbonylamino-propanoic acid trans-d-phenylalanine ay4166 Stsis A-4166 (-)-N-(trans-4-Isopropylcyclohexyl-1-carbonyl)-D-phenylalanine |
| Description | Nateglinide is an insulin secretagog agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).Target: OthersNateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those na?ve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound [1-3]. |
|---|---|
| Related Catalog | |
| References |
[1]. http://205.193.93.51/dpdonline/searchRequest.dodin=2245439 |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 527.6±39.0 °C at 760 mmHg |
| Melting Point | 137-141ºC |
| Molecular Formula | C19H27NO3 |
| Molecular Weight | 317.423 |
| Flash Point | 272.9±27.1 °C |
| Exact Mass | 317.199097 |
| PSA | 66.40000 |
| LogP | 4.21 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.536 |
| Storage condition | Room temp |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R22 |
| Safety Phrases | 24/25-36 |
| RIDADR | NONH for all modes of transport |
| RTECS | SQ7318950 |
| HS Code | 2924299090 |
| Precursor 8 | |
|---|---|
| DownStream 1 | |
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |